Molecule Information

General Information of the Molecule (ID: Mol02156)

• Name: HLA complex P5 (HCP5) ,Homo sapiens
• Synonyms: HCP5
• Molecule Type: LncRNA
• Gene Name: HCP5
• Gene ID: 10866
• Location: chr6:31,463,170-31,478,936[+]
• Ensembl ID: ENSG00000206337
• HGNC ID: HGNC:21659

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Investigative Drug(s) 1 drug(s) in total

Cisplatinum

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Triple negative breast cancer [1]

• Resistant Disease: Triple negative breast cancer [ICD-11: 2C60.9]
• Resistant Drug: Cisplatinum
• Molecule Alteration: Down-regulation; Expression
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: MDA-MB-231; Pleural effusion; Homo sapiens (Human); CVCL_0062
• In Vivo Model: BALB/c nude mice xenograft model; Mus musculus
• Experiment for Molecule Alteration: Microarray assay; Western bloting analysis; Overexpression assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: The downregulation of HCP5 contributed to DDP resistance in TNBC, while overexpression of HCP5 reversed the resistance via upregulating PTEN level.

References

• Ref 1: Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expressionBiomed Pharmacother. 2019 Jul;115:108869. doi: 10.1016/j.biopha.2019.108869. Epub 2019 Apr 24.